ReviewCurrent medicinal chemistry2026
MiRNA Regulations in Cardiotoxicity Induced by Oncologic Therapies and Possible Immune Response.
Review in Current medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Anti-cancer therapy offers significant risks for cardiovascular diseases, including hypertension, thromboembolic ischaemia, arrhythmias, dyslipidaemia, hyperglycemia, obesity, and high cholesterol. Cardiotoxicity is a leading cause of elevated mortality rates among cancer patients, and anti-cancer drugs often contribute to this issue. Emerging research highlights the role of microRNA (miRNAs) in regulating drug-induced cardiotoxicity by influencing genetic, epigenetic, transcriptional, and translational processes. MiRNAs have potential as biomarkers for early detection and treatment. Moreover, novel diagnostic and therapeutic approaches targeting miRNAs could improve the clinical management of cardiotoxicity in cancer patients. This study is based on regulatory mechanisms behind cardiotoxicity, including oxidative stress, vascular homeostasis, mitochondrial damage, apoptosis, and inflammation, and explores strategies for managing these complications in cancer therapy.
Indexed as
Identifiers
40917031What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.